Department of Haematology, Westmead Hospital, Sydney, NSW, Australia.
Stem Cell Transplant and Cell Therapies Program, Westmead Hospital, Sydney, NSW, Australia.
Transpl Infect Dis. 2021 Apr;23(2):e13528. doi: 10.1111/tid.13528. Epub 2020 Dec 6.
Viral infections, principally cytomegalovirus, Epstein Barr virus (EBV) and adenovirus, are a leading cause of morbidity and mortality after allogeneic stem cell transplantation. The use of systemic antivirals is limited by limited efficacy and organ toxicities. Inability to clear infection is exacerbated by transplant-related immunosuppression and prophylaxis or treatment of acute graft versus host disease. We report the first patient to clear three serious viral infections after stem cell transplant using third-party donor partially human leukocyte antigen (HLA) matched virus-specific cytotoxic T cells. The patient, a 53 year old female with transplanted for relapsed leukemia, with severe graft versus host disease received five T cell infusions from three separate donors that ultimately cleared serious systemic infections with cytomegalovirus and adenovirus, and an EBV-driven lymphoma. Systemic antivirals had resulted in failed clinical responses. Use of repeated infusions of partially HLA matched virus-specific T cells from banks containing cryopreserved cells should be strongly considered in transplant recipients with single or multiple refractory viral infections.
病毒感染,主要是巨细胞病毒、Epstein Barr 病毒(EBV)和腺病毒,是异基因干细胞移植后发病率和死亡率的主要原因。由于疗效有限和器官毒性,全身抗病毒药物的使用受到限制。移植相关免疫抑制以及急性移植物抗宿主病的预防或治疗加剧了无法清除感染的情况。我们报告了首例使用第三方供体部分人白细胞抗原(HLA)匹配的病毒特异性细胞毒性 T 细胞清除干细胞移植后三种严重病毒感染的患者。该患者为 53 岁女性,因复发白血病接受移植,伴有严重移植物抗宿主病,从三名供体接受了五次 T 细胞输注,最终清除了严重的全身巨细胞病毒和腺病毒感染以及 EBV 驱动的淋巴瘤。系统性抗病毒药物治疗导致临床反应失败。对于患有单一或多种难治性病毒感染的移植受者,应强烈考虑使用来自含有冷冻细胞的银行的重复输注部分 HLA 匹配的病毒特异性 T 细胞。